Mesenchymal Stem Cells Market Report 2026

Mesenchymal Stem Cells Market Overview

• Mesenchymal Stem Cells market size has reached to $3.81 billion in 2025 • Expected to grow to $6.54 billion in 2030 at a compound annual growth rate (CAGR) of 11.1% • Growth Driver: Regenerative Medicine Driving Growth in the Mesenchymal Stem Cell (MSC) Market • Market Trend: Innovative GMP-Compliant Products Strengthen The Mesenchymal Stem Cells Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Mesenchymal Stem Cells Market?

Mesenchymal stem cells (MSCs) refer to a type of multipotent adult stem cells found in various tissues throughout the body, including bone marrow, adipose tissue, umbilical cord blood, and dental pulp. These cells, which have the ability to differentiate into a variety of cell types, including osteoblasts (bone cells) and chondrocytes (cartilage cells), are used in the treatment of various conditions, including bone and cartilage repair, myocardial infarction, and neurological disorders. The main types of mesenchymal stem cells are autologous and allogeneic. Autologous refers to a medical procedure or treatment where cells, tissues, or substances are obtained from an individual and then reintroduced into the same individual. The various product types include cells and cell lines, kits, media and reagents, and others, along with various workflow types, such as cell sourcing and isolation, culture and cryopreservation, differentiation, and characterization. These are used for several indications, including bone and cartilage repair, cardiovascular diseases, inflammatory and immunological diseases, liver diseases, cancer, GvHD, and others, and in various applications, such as disease modeling, drug development and discovery, stem cell banking, tissue engineering, toxicology studies, and others.

What Is The Mesenchymal Stem Cells Market Growth Forecast?

The mesenchymal stem cells market size is expected to see rapid growth in the next few years. It will grow to $6.54 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to growing demand for regenerative medicine, rising commercialization of allogeneic therapies, development of advanced cell culture systems, growth in personalized stem cell treatments, increasing investment in clinical trials. Major trends in the forecast period include advancement in regenerative medicine development, AI-supported stem cell characterization, automated bioprocessing and cell expansion, cloud-integrated msc research data platforms, growth in sustainable cell culture technologies.

Global Mesenchymal Stem Cells Market Segmentation

1) By Type: Autologous, Allogeneic 2) By Materials And Tools: Cells And Cell Lines, Kits, Media And Reagents, Other Materials And Tools 3) By Workflow Type: Cell Sourcing And Isolation, Culture And Cryopreservation, Differentiation, Characterization 4) By Indication: Bone And Cartilage Repair, Cardiovascular Diseases, Inflammatory And Immunological Diseases, Liver Diseases, Cancer, GvHD, Other Indications 5) By Application: Disease Modeling, Drug Development And Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies, Other Applications Subsegments: 1) By Autologous: Bone Marrow-Derived, Adipose Tissue-Derived, Cord Blood-Derived, Peripheral Blood-Derived 2) By Allogeneic: Bone Marrow-Derived, Umbilical Cord-Derived, Placental-Derived, Induced Pluripotent Stem Cells (iPSCs) Derived, Wharton's Jelly-Derived

What Is The Driver Of The Mesenchymal Stem Cells Market?

The growing awareness regarding regenerative medicine is expected to propel the growth of the mesenchymal stem cells (MSC) market going forward. Regenerative medicine is an emerging interdisciplinary field that focuses on the repair, replacement, or regeneration of cells, tissues, or organs to restore impaired function resulting from any cause, including congenital defects, disease, trauma, and aging. Regenerative medicine is increasing due to several key factors, such as growing clinical trials, the growing incidence of chronic conditions, age-related conditions, and personalized medicine. Mesenchymal stem cells (MSCs) offer significant potential in regenerative medicine due to their ability to differentiate into multiple cell types, modulate immune responses, and promote tissue repair and regeneration across a wide range of medical conditions. For instance, in August 2023, according to a report by the Alliance for Regenerative Medicine, a US-based non-profit organization, there were 2,760 cells, gene, and tissue-engineering therapeutic developers worldwide in Q1 2023, up 101% since 1,369 in Q1 2022. Furthermore, in July 2023, according to the report published by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, at the end of Q1 2023, there were 247 gene therapies in Phase II, but this number rose by 5% to reach 260 by the end of Q2. Therefore, growing awareness regarding regenerative medicine is driving the growth of the mesenchymal stem cell (MSC) market.

Key Players In The Global Mesenchymal Stem Cells Market

Major companies operating in the mesenchymal stem cells market are Thermo Fischer Scientific Inc., Danaher Corporation, Merck KgaA, Becton, Dickinson, and Company, Fujifilm Holdings Corporation, Corning Inc., Daiichi Sankyo, Lonza Group, Terumo Corporation, Sartorius AG, Getinge AB, Bio-Rad Laboratories, Eppendorf AG, Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec GmBH, Takara Bio Group, Organogenesis Holdings Inc., Vericel Corporation, HiMedia Laboratories, PromoCell GmbH, CellGenix GmBH, Anterogen Co. Ltd., Pluristem Therapeutics Inc., American Cryostem Corporation

Global Mesenchymal Stem Cells Market Trends and Insights

Major companies operating in the mesenchymal stem cells (MSCs) market are adopting innovative technologies, such as GMP-compliant isolation, to strengthen their position in the market. GMP (Good Manufacturing Practice)-compliant isolation refers to the process of isolating cells, including mesenchymal stem cells (MSCs), according to GMP regulations to ensure consistent production and control of product quality. For instance, in July 2023, PromoCell, a Germany-based biotechnology company, announced the launch of PromoExQ MSC Growth Medium XF, a serum- and xeno-free medium designed for the expansion of human mesenchymal stem cells (MSCs) in a Good Manufacturing Practice (GMP)-regulated environment. This medium is manufactured under the highest quality standards and is certified by the EXCiPACT GMP certification scheme, ensuring consistent growth and maintenance of MSCs from various sources such as bone marrow, umbilical cord matrix, and adipose tissue.

What Are Latest Mergers And Acquisitions In The Mesenchymal Stem Cells Market?

In May 2024, BioSolution Designs ((BSD), a US-based biotechnology invention studio, partnered with RoosterBio, Inc. The partnership focuses on simplifying the development and production of engineered human mesenchymal stem/stromal cell (MSC)-derived therapies and exosome-based therapies by integrating BSD’s multigenic design platform with RoosterBio’s cell processing and scalable manufacturing capabilities. Together, they aim to fast-track the clinical advancement of next-generation cell therapies. RoosterBio, Inc. is a US-based developer of adult human mesenchymal stem/stromal cells (hMSCs).

Regional Outlook

North America was the largest region in the mesenchymal stem cells market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Mesenchymal Stem Cells Market?

The mesenchymal stem cells market consists of revenues earned by entities by providing services such as cell isolation and culture techniques, cryopreservation and storage, custom cell development, and MSC-based therapeutics development. The market value includes the value of related goods sold by the service provider or included within the service offering. The mesenchymal stem cells market also includes sales of MSC differentiation inducers, scaffolds and matrices, MSC-derived exosomes, and cryopreservation agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Mesenchymal Stem Cells Market Report 2026?

The mesenchymal stem cells market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mesenchymal stem cells industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.